MedPath

sefulness of FAMT-PET to predict the response after chemotherapy in patients withmalignant lymphoma

Not Applicable
Conditions
malignant lymphoma
Registration Number
JPRN-UMIN000025980
Lead Sponsor
Gunma Univetsity
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1) Pregnant woman 2) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3) Patients with collagen vascular disease or autoimmune diseases 4) Other cases attending physician it is determined unsuitable for registration of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changeing of SUVmax, MTV and TLG, and the efficacy of chemotherapy Evaluation after 2 cycles from initial chemotherapy
Secondary Outcome Measures
NameTimeMethod
Survival and adverse events
© Copyright 2025. All Rights Reserved by MedPath